Clinical Trial Detail

NCT ID NCT02018861
Title A Phase 1, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 Monotherapy and in Combination With INCB039110 in Subjects With Previously Treated B-Cell Malignancies
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements no
Sponsors Incyte Corporation
Indications

Hodgkin's lymphoma

non-Hodgkin lymphoma

hairy cell leukemia

mantle cell lymphoma

chronic lymphocytic leukemia

B-cell lymphoma

Therapies

Itacitinib

Itacitinib + Parsaclisib

Bendamustine

Rituximab

Carboplatin + Etoposide + Ifosfamide

Parsaclisib

Age Groups: adult

No variant requirements are available.